Coffee Talk: Why is Digital Health Important to Biopharmaceutical Companies?
The pandemic has illustrated how Social Determinants of Health (SDOH) can impact the spread of disease, access to vaccines and the levels of trust in and utilization of basic health services.
Beyond the focus on SDOH by politicians, advocacy, groups, and charitable organizations, there are private and public commercial organizations that make it a priority to find and fund solutions that address the social and cultural barriers that reduce or limit access to care.
One of those organizations is Bayer.
In this conversation with Dominick Kennerson, Global Head of Bayer G4A, we discuss how equity, access and sustainability help set the course for their investment strategy.
This Coffee Talk is created in partnership with our Sponsor, Bayer G4A. This year Bayer G4A is looking for companies creating solutions to 5 key challenges including oncology, radiology, mental health, women’s health and cardio metabolic and renal diseases.
The Bayer G4A program is open to companies from pre-seed stage to Series A, and even more advanced companies with traction in the market. Apply to be a part of Bayer G4A here, and tell them you heard about it on Digital Health Today.
The deadline to apply is June 20, 2021.
Guest Links and Resources:
- Connect with Dom Kennerson: Twitter | LinkedIn
- Connect with Bayer G4A: Website | Twitter | LinkedIn | YouTube
- World Health Organization – Website | Constitution
Host Links
Connect on Digital Health Today:
Browse Episodes | Twitter | Linkedin | Facebook | Instagram
Connect on Health Podcast Network:
Browse Shows | Linkedin | Twitter | Facebook | Instagram
